Well, here we are again, asking more questions....
So, as you might have inferred from a previous post, our oncologist is confering with his tumor board today on recommendations for my wife's next treatments, and we should hear back tomorrow.
My question relates to one of the options, continuing with abraxane but adding ramucirumab. I have tried to look it up, but I am not clear on the real side-effect profile that increases with ramucirumab. I see that there are vascular risks (e.g. arterial perforation), bleeding (e.g. nose), as well as nausea, low white cells, and rash. But since many of these studies are from ramucirumab cases with different combinations of other drugs, it is hard to tease apart what the increased frequency of side-effects is with abraxane. For example, the side effects with old style paclitaxel alone are much greater than with abraxane alone, yet many of the studies seem to have been done with paclitaxel and ramucirumab.
I guess my question is whether there is a clinical sense (or anecdotal sense for anyone out there reading this) of what the intensity and frequency of increased side effects are for the ramucirumab when given with abraxane. We may not even be going this route, but if we do we want to know what side effects to prepare for.